Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
Please note that the ANZCTR website will be unavailable from 9am until 12:30pm (AEDT) on Tuesday 17th November for website maintenance.
Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05243797
Registration number
NCT05243797
Ethics application status
Date submitted
27/01/2022
Date registered
17/02/2022
Date last updated
10/11/2026
Titles & IDs
Public title
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Query!
Scientific title
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
Query!
Additional trial identifiers [1]
0
0
EMN30/64007957MMY3003
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
MajesTEC-4
Query!
Related trial records
Query!
Health condition
Health condition(s) studied:
Multiple Myeloma
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of the intervention or exposure
Treatment: Drugs - Teclistamab
Treatment: Drugs - Lenalidomide
Experimental: Arm A: Teclistamab-Lenalidomide (Tec-Len) - Teclistamab will be administered via a subcutaneous injection (SC)
Active comparator: Arm B Lenalidomide Alone (Len) - Lenalidomide orally.
Experimental: Arm C Teclistamab-Alone (Tec) - Teclistamab will be administered via a subcutaneous injection (SC)
Treatment: Drugs: Teclistamab
Teclistamab will be administered via a subcutaneous injection (SC)
Treatment: Drugs: Lenalidomide
Lenalidomide will be administered orally
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Description of the comparator or control
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression Free Survival (PFS)
Query!
Assessment method [1]
0
0
PFS is defined as the time from the date of randomization to the date of disease progression (as assessed by IMWG criteria) or death due to any cause, whichever occurs first.
Query!
Timepoint [1]
0
0
from randomization to the date of disease progression or death (approximately up to 8 years)
Query!
Primary outcome [2]
0
0
Minimal Residual Disease (MRD)-negative Complete Response (CR)
Query!
Assessment method [2]
0
0
12-month MRD-negative CR is defined as participants who achieve MRD-negative status at 12 months, as determined by next-generation flow cytometry (NGF) with sensitivity of 10\^-5, prior to progressive disease or subsequent anti-myeloma therapy, whichever is earlier, and who also achieve CR of better, according to IMWG criteria.
Query!
Timepoint [2]
0
0
at month 12
Query!
Secondary outcome [1]
0
0
Comparison of efficacy
Query!
Assessment method [1]
0
0
Efficacy, assessed by rate of CR or better, MRD negative CR, sustained MRD negativity, CR and MRD negative conversion PFS after next line of therapy (PFS2), time to next treatment (TTNT), OS and also safety, PK and immunogenicity
Query!
Timepoint [1]
0
0
from randomization to the date of disease progression or death (approximately up to 8 years)
Query!
Secondary outcome [2]
0
0
Overall Survival (OS)
Query!
Assessment method [2]
0
0
Overall Survival (OS), measured from the date of from randomization to the date the subject's death
Query!
Timepoint [2]
0
0
from the date of from randomization to the date the subject's death, assessed up to 8 years]
Query!
Secondary outcome [3]
0
0
Change in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core module (EORTC QLQ-C30) score and the difference between-treatment arms
Query!
Assessment method [3]
0
0
The EORTC QLQ-C30 is a 30-item questionnaire containing both single and multi-item measures. These include five functional scales (Physical, Role, Cognitive, Emotional, and Social Functioning), three symptom scales (Fatigue, Pain, and Nausea/Vomiting), a Global Health Status/ Quality-of-Life (QoL) scale, and six single items (Constipation, Diarrhea, Insomnia, Dyspnea, Appetite Loss, and Financial Difficulties). The scores ranges from 0-100, a high score for functional scales and for Global Health Status/QoL represent better functioning ability or Health-Related Quality-of-Life (HRQoL), whereas a high score for symptom scales and single items represents significant symptomatology.
Query!
Timepoint [3]
0
0
baseline up to 8 years
Query!
Secondary outcome [4]
0
0
EQ-5D-5L health utility values and the difference between-treatment arms
Query!
Assessment method [4]
0
0
The EQ-5D-5L is a 5 item questionnaire that assesses 5 domains including mobility, self care, usual activities, pain/discomfort, and anxiety/depression plus a visual analog scale rating "health today"
Query!
Timepoint [4]
0
0
baseline up to 8 years
Query!
Secondary outcome [5]
0
0
MySIm-Q Symptom and Impacts in Patients With Multiple Myeloma and the difference between treatment arms
Query!
Assessment method [5]
0
0
The MySIm-Q is a disease-specific PRO assessment complementary to the EORTC-QLQ-C30. It includes 17 items resulting in a symptom subscale and an impact subscale. The recall period is the "past 7 days", and responses are reported on a 5-point verbal rating scale.
Query!
Timepoint [5]
0
0
baseline up to 8 years
Query!
Secondary outcome [6]
0
0
PRO-CTCAE to evaluate symptomatic toxicities by self-report and the difference between treatment arms
Query!
Assessment method [6]
0
0
The PRO-CTCAE Measurement System characterizes the frequency, severity, interference, and presence/absence of symptomatic toxicities. The PRO-CTCAE Item Library includes 124 items representing 78 symptomatic toxicities drawn from the CTCAE
Query!
Timepoint [6]
0
0
baseline up to week 24
Query!
Secondary outcome [7]
0
0
PGIS to evaluate the patient global impression of severity of the Multiple Myeloma and the difference between treatment arms
Query!
Assessment method [7]
0
0
PGIS is a 1 item questionnaire that evaluates patients' health and assesses if there has been an improvement or decline in clinical status
Query!
Timepoint [7]
0
0
baseline up to 8 years
Query!
Eligibility
Key inclusion criteria
* Must have a new diagnosis of multiple myeloma according to IMWG criteria and have received induction +/- consolidation.
* Must have received only one line of therapy and achieved at least a partial response (=PR) as per IMWG 2016 response criteria (Kumar 2016) without evidence of progression at the time of first treatment dose.
* Must not be intolerant to the starting dose of lenalidomide.
* Must not have received any maintenance therapy.
* Have an ECOG performance status score of 0, 1, or 2 at screening and immediately prior to the start of administration of study treatment
* Have clinical laboratory values within prespecified range.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Healthy volunteers
No
Query!
Key exclusion criteria
* Received any prior BCMA-directed therapy.
* Any previous therapy with an immune cell redirecting agent or gene modified adoptive cell therapy (eg, chimeric antigen receptor modified T cells, NK cells).
* Discontinued treatment due to any AE related to lenalidomide as determined by the investigator.
* Progressed on multiple myeloma therapy at any time prior to screening.
* Received a cumulative dose of corticosteroids equivalent to =140 mg of prednisone within the 14 days prior to first treatment dose.
* Received a live, attenuated vaccine within 4 weeks before first treatment dose. Non-live vaccines or non-replicating authorized for emergency use (eg. COVID-19) are allowed.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
8/09/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/04/2032
Query!
Actual
Query!
Sample size
Target
1594
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Flinders Medical Centre - Adelaide
Query!
Recruitment hospital [2]
0
0
Sunshine Coast Health - Birtinya
Query!
Recruitment hospital [3]
0
0
Townsville University Hospital - Douglas
Query!
Recruitment hospital [4]
0
0
Barwon Health University Hospital Geelong Andrew Love Cancer Centre - Geelong
Query!
Recruitment hospital [5]
0
0
Alfred Hospital - Melbourne
Query!
Recruitment hospital [6]
0
0
Austin Health - Melbourne
Query!
Recruitment hospital [7]
0
0
Calvary Mater Hospital - Newcastle
Query!
Recruitment hospital [8]
0
0
Concord Repatriation General Hospital - Sydney
Query!
Recruitment hospital [9]
0
0
Royal North Shore Hospital - Sydney
Query!
Recruitment postcode(s) [1]
0
0
- Adelaide
Query!
Recruitment postcode(s) [2]
0
0
- Birtinya
Query!
Recruitment postcode(s) [3]
0
0
- Douglas
Query!
Recruitment postcode(s) [4]
0
0
- Geelong
Query!
Recruitment postcode(s) [5]
0
0
- Melbourne
Query!
Recruitment postcode(s) [6]
0
0
- Newcastle
Query!
Recruitment postcode(s) [7]
0
0
- Sydney
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Delaware
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
District of Columbia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Georgia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Illinois
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Maryland
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Massachusetts
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New York
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
North Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Ohio
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Pennsylvania
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
South Carolina
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Tennessee
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Texas
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Virginia
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Wisconsin
Query!
Country [21]
0
0
Argentina
Query!
State/province [21]
0
0
Buenos Aires
Query!
Country [22]
0
0
Argentina
Query!
State/province [22]
0
0
Córdoba
Query!
Country [23]
0
0
Argentina
Query!
State/province [23]
0
0
Rosario
Query!
Country [24]
0
0
Austria
Query!
State/province [24]
0
0
Feldkirch
Query!
Country [25]
0
0
Austria
Query!
State/province [25]
0
0
Innsbruck
Query!
Country [26]
0
0
Austria
Query!
State/province [26]
0
0
Krems
Query!
Country [27]
0
0
Austria
Query!
State/province [27]
0
0
Linz
Query!
Country [28]
0
0
Austria
Query!
State/province [28]
0
0
Salzburg
Query!
Country [29]
0
0
Austria
Query!
State/province [29]
0
0
Vienna
Query!
Country [30]
0
0
Belgium
Query!
State/province [30]
0
0
Hasselt
Query!
Country [31]
0
0
Belgium
Query!
State/province [31]
0
0
La Louvière
Query!
Country [32]
0
0
Belgium
Query!
State/province [32]
0
0
Leuven
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Liège
Query!
Country [34]
0
0
Belgium
Query!
State/province [34]
0
0
Roeselare
Query!
Country [35]
0
0
Brazil
Query!
State/province [35]
0
0
Porto Alegre
Query!
Country [36]
0
0
Brazil
Query!
State/province [36]
0
0
Rio de Janeiro
Query!
Country [37]
0
0
Brazil
Query!
State/province [37]
0
0
Salvador
Query!
Country [38]
0
0
Brazil
Query!
State/province [38]
0
0
São Paulo
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Edmonton
Query!
Country [40]
0
0
Canada
Query!
State/province [40]
0
0
Halifax
Query!
Country [41]
0
0
Canada
Query!
State/province [41]
0
0
Ottawa
Query!
Country [42]
0
0
Canada
Query!
State/province [42]
0
0
Saskatoon
Query!
Country [43]
0
0
Canada
Query!
State/province [43]
0
0
Sherbrooke
Query!
Country [44]
0
0
Canada
Query!
State/province [44]
0
0
Toronto
Query!
Country [45]
0
0
Canada
Query!
State/province [45]
0
0
Vancouver
Query!
Country [46]
0
0
China
Query!
State/province [46]
0
0
Beijing
Query!
Country [47]
0
0
China
Query!
State/province [47]
0
0
Changchun
Query!
Country [48]
0
0
China
Query!
State/province [48]
0
0
Henan
Query!
Country [49]
0
0
China
Query!
State/province [49]
0
0
Shandong
Query!
Country [50]
0
0
China
Query!
State/province [50]
0
0
Shanghai
Query!
Country [51]
0
0
China
Query!
State/province [51]
0
0
Shenyang
Query!
Country [52]
0
0
China
Query!
State/province [52]
0
0
Tangshan
Query!
Country [53]
0
0
China
Query!
State/province [53]
0
0
Tianjin
Query!
Country [54]
0
0
China
Query!
State/province [54]
0
0
Wenzhou
Query!
Country [55]
0
0
China
Query!
State/province [55]
0
0
Wuhan
Query!
Country [56]
0
0
China
Query!
State/province [56]
0
0
Zhejiang
Query!
Country [57]
0
0
Czechia
Query!
State/province [57]
0
0
Hradec Králové
Query!
Country [58]
0
0
Czechia
Query!
State/province [58]
0
0
Olomouc
Query!
Country [59]
0
0
Czechia
Query!
State/province [59]
0
0
Ostrava
Query!
Country [60]
0
0
Czechia
Query!
State/province [60]
0
0
Pilsen
Query!
Country [61]
0
0
Czechia
Query!
State/province [61]
0
0
Prague
Query!
Country [62]
0
0
Denmark
Query!
State/province [62]
0
0
Aarhus
Query!
Country [63]
0
0
Denmark
Query!
State/province [63]
0
0
Copenhagen
Query!
Country [64]
0
0
Denmark
Query!
State/province [64]
0
0
Odense
Query!
Country [65]
0
0
Denmark
Query!
State/province [65]
0
0
Vejle
Query!
Country [66]
0
0
France
Query!
State/province [66]
0
0
Bordeaux
Query!
Country [67]
0
0
France
Query!
State/province [67]
0
0
Lille
Query!
Country [68]
0
0
France
Query!
State/province [68]
0
0
Marseille
Query!
Country [69]
0
0
France
Query!
State/province [69]
0
0
Montpellier
Query!
Country [70]
0
0
France
Query!
State/province [70]
0
0
Nantes
Query!
Country [71]
0
0
France
Query!
State/province [71]
0
0
Paris
Query!
Country [72]
0
0
France
Query!
State/province [72]
0
0
Poitiers
Query!
Country [73]
0
0
France
Query!
State/province [73]
0
0
Toulouse
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
Hamburg
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Heidelberg
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Jena
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
Lübeck
Query!
Country [78]
0
0
Germany
Query!
State/province [78]
0
0
München
Query!
Country [79]
0
0
Germany
Query!
State/province [79]
0
0
Nuremberg
Query!
Country [80]
0
0
Germany
Query!
State/province [80]
0
0
Tübingen
Query!
Country [81]
0
0
Germany
Query!
State/province [81]
0
0
Würzburg
Query!
Country [82]
0
0
Greece
Query!
State/province [82]
0
0
Alexandroupoli
Query!
Country [83]
0
0
Greece
Query!
State/province [83]
0
0
Athens
Query!
Country [84]
0
0
Greece
Query!
State/province [84]
0
0
Thessaloniki
Query!
Country [85]
0
0
Ireland
Query!
State/province [85]
0
0
Cork
Query!
Country [86]
0
0
Ireland
Query!
State/province [86]
0
0
Dublin
Query!
Country [87]
0
0
Ireland
Query!
State/province [87]
0
0
Galway
Query!
Country [88]
0
0
Ireland
Query!
State/province [88]
0
0
Limerick
Query!
Country [89]
0
0
Israel
Query!
State/province [89]
0
0
Beersheba
Query!
Country [90]
0
0
Israel
Query!
State/province [90]
0
0
Haifa
Query!
Country [91]
0
0
Israel
Query!
State/province [91]
0
0
Jerusalem
Query!
Country [92]
0
0
Israel
Query!
State/province [92]
0
0
Petah Tikva
Query!
Country [93]
0
0
Israel
Query!
State/province [93]
0
0
Ramat Gan
Query!
Country [94]
0
0
Israel
Query!
State/province [94]
0
0
Tel Aviv
Query!
Country [95]
0
0
Italy
Query!
State/province [95]
0
0
Alessandria
Query!
Country [96]
0
0
Italy
Query!
State/province [96]
0
0
Ancona
Query!
Country [97]
0
0
Italy
Query!
State/province [97]
0
0
Bari
Query!
Country [98]
0
0
Italy
Query!
State/province [98]
0
0
Bergamo
Query!
Country [99]
0
0
Italy
Query!
State/province [99]
0
0
Bologna
Query!
Country [100]
0
0
Italy
Query!
State/province [100]
0
0
Brescia
Query!
Country [101]
0
0
Italy
Query!
State/province [101]
0
0
Cagliari
Query!
Country [102]
0
0
Italy
Query!
State/province [102]
0
0
Cosenza
Query!
Country [103]
0
0
Italy
Query!
State/province [103]
0
0
Florence
Query!
Country [104]
0
0
Italy
Query!
State/province [104]
0
0
Genova
Query!
Country [105]
0
0
Italy
Query!
State/province [105]
0
0
Milan
Query!
Country [106]
0
0
Italy
Query!
State/province [106]
0
0
Modena
Query!
Country [107]
0
0
Italy
Query!
State/province [107]
0
0
Naples
Query!
Country [108]
0
0
Italy
Query!
State/province [108]
0
0
Novara
Query!
Country [109]
0
0
Italy
Query!
State/province [109]
0
0
Padova
Query!
Country [110]
0
0
Italy
Query!
State/province [110]
0
0
Parma
Query!
Country [111]
0
0
Italy
Query!
State/province [111]
0
0
Pavia
Query!
Country [112]
0
0
Italy
Query!
State/province [112]
0
0
Pescara
Query!
Country [113]
0
0
Italy
Query!
State/province [113]
0
0
Ravenna
Query!
Country [114]
0
0
Italy
Query!
State/province [114]
0
0
Reggio Emilia
Query!
Country [115]
0
0
Italy
Query!
State/province [115]
0
0
Rimini
Query!
Country [116]
0
0
Italy
Query!
State/province [116]
0
0
Roma
Query!
Country [117]
0
0
Italy
Query!
State/province [117]
0
0
San Giovanni Rotondo
Query!
Country [118]
0
0
Italy
Query!
State/province [118]
0
0
Torino
Query!
Country [119]
0
0
Italy
Query!
State/province [119]
0
0
Trieste
Query!
Country [120]
0
0
Italy
Query!
State/province [120]
0
0
Udine
Query!
Country [121]
0
0
Netherlands
Query!
State/province [121]
0
0
Alkmaar
Query!
Country [122]
0
0
Netherlands
Query!
State/province [122]
0
0
Amsterdam
Query!
Country [123]
0
0
Netherlands
Query!
State/province [123]
0
0
Dordrecht
Query!
Country [124]
0
0
Netherlands
Query!
State/province [124]
0
0
Eindhoven
Query!
Country [125]
0
0
Netherlands
Query!
State/province [125]
0
0
Groningen
Query!
Country [126]
0
0
Netherlands
Query!
State/province [126]
0
0
Hoorn
Query!
Country [127]
0
0
Netherlands
Query!
State/province [127]
0
0
Nieuwegein
Query!
Country [128]
0
0
Netherlands
Query!
State/province [128]
0
0
Rotterdam
Query!
Country [129]
0
0
Norway
Query!
State/province [129]
0
0
Trondheim
Query!
Country [130]
0
0
Poland
Query!
State/province [130]
0
0
Gdansk
Query!
Country [131]
0
0
Poland
Query!
State/province [131]
0
0
Poznan
Query!
Country [132]
0
0
Portugal
Query!
State/province [132]
0
0
Lisbon
Query!
Country [133]
0
0
Portugal
Query!
State/province [133]
0
0
Vila Real
Query!
Country [134]
0
0
Serbia
Query!
State/province [134]
0
0
Belgrade
Query!
Country [135]
0
0
Serbia
Query!
State/province [135]
0
0
Kragujevac
Query!
Country [136]
0
0
Serbia
Query!
State/province [136]
0
0
Niš
Query!
Country [137]
0
0
Serbia
Query!
State/province [137]
0
0
Novi Sad
Query!
Country [138]
0
0
South Korea
Query!
State/province [138]
0
0
Gwangju
Query!
Country [139]
0
0
South Korea
Query!
State/province [139]
0
0
Seoul
Query!
Country [140]
0
0
Switzerland
Query!
State/province [140]
0
0
Basel
Query!
Country [141]
0
0
Switzerland
Query!
State/province [141]
0
0
Bern
Query!
Country [142]
0
0
Switzerland
Query!
State/province [142]
0
0
Sankt Gallen
Query!
Country [143]
0
0
Turkey (Türkiye)
Query!
State/province [143]
0
0
Ankara
Query!
Country [144]
0
0
Turkey (Türkiye)
Query!
State/province [144]
0
0
Istanbul
Query!
Country [145]
0
0
Turkey (Türkiye)
Query!
State/province [145]
0
0
Izmir
Query!
Country [146]
0
0
Turkey (Türkiye)
Query!
State/province [146]
0
0
Kayseri
Query!
Country [147]
0
0
United Kingdom
Query!
State/province [147]
0
0
London
Query!
Country [148]
0
0
United Kingdom
Query!
State/province [148]
0
0
Sutton
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
European Myeloma Network B.V.
Query!
Address
Query!
Country
Query!
Secondary sponsor
Nil
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Janssen Pharmaceutica
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.
Query!
Trial website
https://clinicaltrials.gov/study/NCT05243797
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Niels van de Donk, Professor
Query!
Address
0
0
Amsterdam UMC, Vrije Universiteit Amsterdam
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Christine Witty
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
+31 10 268 70 65
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT05243797
Download to PDF